ADC Therapeutics Q1 net loss narrows to $46.6M; ZYNLONTA sales $17.8M; initial MZL data shows 13/15 CR

ADC Therapeutics SA

2024-Q1 EPS reported -$0.56 revenue$18,053,000

ZYNLONTA net sales $17.8M in Q1 2024, up 7% QoQ, down 6% YoY; total operating expenses down 25%.
Net loss $46.6M ($0.56/share) vs $59.4M ($0.73) in Q1 2023; adjusted net loss $31.1M.
Cash $234.3M as of Mar 31, 2024; cash runway expected into Q4 2025.
LOTIS-5 enrollment on track to complete in 2024; LOTIS-7 dose escalation complete, expansion initiated.
Initial Phase 2 IIT data in r/r MZL: 15 evaluable patients, 13 complete responses (CR) and 1 PR.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ADC Therapeutics SA reported financial results for the first quarter ended March 31, 2024.

Period: the first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 6, 2024, ADC Therapeutics SA (the “Company”) issued a press release announcing the Company’s financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

ADC Therapeutics SA filing history →

Source: SEC EDGAR

accession 0001628280-24-020447

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.